Approaches, such as those highlighted in the current study, including atrogin-1 upregulation or BiP inhibition, will likely be needed to complement gene-based interventions for the treatment of DMD and other muscle wasting disorders. This evidence concerns the gene FBXO32 and Duchenne muscular dystrophy.